Roche: Phase III SKYSCRAPER-02 Study In ES-SCLC Fails To Meet Co-primary Endpoint

SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche Holding AG (RHHBY) announced Wednesday that the phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer or ES-SCLC did not

Related Keywords

Switzerland ,Swiss , ,Drug Administration ,Roche Holding ,Breakthrough Therapy Designation ,Roche ,Hase ,Skyscraper ,Study ,Clc ,Nails ,Feet ,Primary ,Ndpoint ,